The complaint filed by Bronstein, Gewirtz & Grossman, LLC centers on claims that Anavex failed to disclose significant operational weaknesses. Specifically, the suit alleges that the company downplayed regulatory challenges linked to the conduct of former CEO Christopher Missling. Plaintiffs argue these omissions rendered public statements about the firm’s business prospects materially false.
In section Releases
Anavex Life Sciences Faces Securities Class Action Lawsuit
Investors who purchased Anavex Life Sciences Corp. securities between November 26, 2025, and August 28, 2026, are being urged to join a newly filed class action lawsuit. The litigation targets the company and specific officers for allegedly misleading shareholders regarding internal controls and regulatory hurdles.
Those who suffered financial losses during the specified period have until November 30, 2026, to petition the court for lead plaintiff status. While this role involves representing the class, investors are eligible to participate in any eventual recovery without serving in that capacity. The firm operates on a contingency fee basis, meaning legal costs are only recovered if the case results in a successful payout for the investors. Interested parties can contact Peretz Bronstein or Nathan Miller at 917-590-0911 for further details regarding the litigation.
Comments (0)
No comments yet. Be the first!